NewEdge Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

NewEdge Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-400	Closed	-$360	–	4233
2026 Q1	$360	Hold	400	–	–	﹤0.01%	4021
2025 Q4	$311	Sell	400 -25,000	-98%	-$31.3K	﹤0.01%	4109
2025 Q3	$31.5K	Buy	25,400 +400	+2%	+$558	﹤0.01%	2980
2025 Q2	$39.8K	Buy	+25,000	New	+$22.9K	﹤0.01%	2735

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

NewEdge Advisors's CTXR Position: Q2 2026 in Review

NewEdge Advisors sold out of Citius Pharmaceuticals (CTXR) in Q2 2026, closing a stake of 400 shares — an estimated $360 sold.

NewEdge Advisors first reported a position in CTXR in Q2 2025 and held it in 4 quarters. The position peaked at $39.8K in Q2 2025. 42 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

NewEdge Advisors reported no remaining Citius Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 400 Citius Pharmaceuticals shares in Q2 2026, an estimated $360.
NewEdge Advisors first reported a position in Citius Pharmaceuticals in Q2 2025 and held it in 4 quarters.
NewEdge Advisors's Citius Pharmaceuticals position peaked at $39.8K in Q2 2025.
42 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.